Stem cell transplantation as consolidation therapy for children in first-remission AML: A single-center report

Pediatric Hematology and Oncology

Volumn 22, Issue 7, 2005, Pages 597-608

  Berger, Massimo ^a   Ferrero, Ivana ^a   Vassallo, Elena ^a   Gastaldo, Luca ^a   Carraro, Francesca ^a   Biasin, Eleonora ^a   Madon, Enrico ^a   Fagioli, Franca ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Acute myeloid leukemia; Children; Stem cell transplantation

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTHRACYCLINE DERIVATIVE; AZITHROMYCIN; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; IMTX; ITRACONAZOLE; MAFOSFAMIDE; MELPHALAN; METHOTREXATE; PENTAMIDINE; PNEUMOCOCCUS VACCINE; THIOTEPA; THYMOCYTE ANTIBODY; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA M7; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BLADDER DISEASE; BLEEDING; BONE MARROW PURGING; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; CELL LINEAGE; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME TRANSLOCATION 9; CLINICAL ARTICLE; CONSOLIDATION THERAPY; CYTOMEGALOVIRUS INFECTION; DONOR; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; GROWTH RETARDATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA MATCHING; HLA TYPING; HUMAN; HYPERLEUKOCYTOSIS; HYPOGONADISM; HYPOTHYROIDISM; INDUCTION CHEMOTHERAPY; LEUKOCYTOSIS; LIVER TOXICITY; LUNG TOXICITY; MALE; MATCHED FAMILIAR DONOR TRANSPLANTATION; MORTALITY; MUCOSA INFLAMMATION; MYCOSIS; MYELODYSPLASIA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PNEUMOCYSTOSIS; RECURRENCE RISK; SHORT COURSE THERAPY; SKIN TOXICITY; STREPTOCOCCUS INFECTION; THROMBOCYTOPENIA; WHOLE BODY RADIATION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW PURGING; CHILD; CHILD, PRESCHOOL; CYTARABINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; IDARUBICIN; INFANT; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 25444486752     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010500198871     Document Type: Article

References (29)

1. Stevens RF, Hann IM, Wheatley K, Gray GR. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. Br J Haematol 1998;101:130-140.
2. Creutzig U, Ritter J, Zimmermann M, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of the Study Acute Myeloid Leukemia Berlin-Frankfurt-Munster 93. J Clin Oncol. 2001;19:2705-2713.
3. Lie SO, Berglund G, Gustafsson G, Jonmundsson G, Siimes M, Yssing M. High-dose Ara-C as a single-agent consolidation therapy in childhood acute myelogenous leukemia. Hematol Bluttransfusion. 1990;33:215-221.
4. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996;87:4979-4989.
5. Woods WG, Neudorf S, Gold S, et al. Children's Cancer Group. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children Cancer Group. Blood. 2001;97:56-62.
6. Burnett AK, Wheakley K, Goldstone AH, et al. Medical Research Council Adult and Paediatric Working Parties. The value of allogeneic bone marrow transplant in patients with acute myeloid leukemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002;118:385-400.
7. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first complete remission. N Engl J Med. 1998;339:1649-1656.
8. Burnett AK, Goldstone AH, Stevens MRF, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: results of MRC AML10 trial. Lancet. 1998;351:700-708.
9. Webb DK, Wheatley K, Harrison G, Stevens RF, Hann IM. Outcome for children with relapsed acute myeloid leukemia following initial therapy in the Medical Research Council (MRC) AML10 trial. Leukemia. 1999;13:25-31.
10. Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. The Pediatric Oncology Group. N Engl J Med. 1996;334:1428-1434.
11. Amadori S, Testi AM, Aricò M, et al. Prospective comparative study of bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. J Clin Oncol. 1993;11:1046-1054.
12. Bonetti F, Zecca M, Pession C, et al. Total body irradiation and melphalan is a safe and effective conditioning regimen for autologous bone marrow transplantation in children with acute myeloid leukemia in first remission. J Clin Oncol. 1999;12:3729-3735.
13. Keung YK, Beaty M, Powell BL, Molnar I, Buss D, Pettenati M. Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia: retrospective study and review of literature. Leuk Res. 2004;28:579-586.
14. Webb DK, Harrison G, Stevens RF, Gibson BG, Kann IM, Wheatley K; MRC Childhood Leukemia Working Party. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood. 2001;98:1714-1720.
15. Garderet L, Labopin M, Gorin NC, et al. Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Blood First Edition Paper, prepublished online June 10, 2004; DOI 10.1182/blood-2004-03-1103.
16. Tallman MS, Neuberg D, Bennett JM, et al. Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood. 2000;96:2405-2411.
17. Pagano L, Pulsoni A, Vignetti M, et al. Acute megakaryoblastic leukemia: experience of GIMEMA trials. Leukemia. 2002;16:1622-1626.
18. Athale UH, Razzouk BI, Raimondi SC, et al. Biology and outcome of childhood acute megakaryocytic leukemia: a single institution's experience. Blood. 2001;97:3727-3732.
19. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562-1568.
20. Fliedner TM, Calvo W, Korbling M, Nothdurft W, Pflieger H, Ross W. Collection, storage and transfusion of blood stem cells for the treatment of hemopoietic failure. Blood Cells. 1979;15:5:313-328.
21. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295-304.
22. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204-217.
23. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
24. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-202.
25. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's leukemia Working Parties. Blood. 1998;92:2322-2333.
26. Zittoun RA, Mandelli F, Willemze R de Witte T, et al., for The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332:217-223.
27. Perel Y, Auvrignon A, Leblanc T, et al. Group LAME of the French Society of Pediatric Hematology and Immunology. Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucamie Aique Myeloide Enfant. J Clin Oncol 2002;20:2774-2782.
28. Abdallah A, Egerer G, Weber-Nordt RM, Korbling M, Haas R, Ho AD. Long-term outcome in acute myelogenous leukemia autografted with mafosfamide-purged marrow in a single institution: adverse events and incidence of myelodysplasia. Bone Marrow Transplant. 2002;30:15-22.
29. Di Grazia C, Raiola AM, Van Lint MT, et al. Conventional hematopoietic stem cell transplants from identical or alternative donors are feasible in recipients relapsing after an autograft. Haematologica. 2001;86:646-651.